Compare LIF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LIF | ACAD |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | 547 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | LIF | ACAD |
|---|---|---|
| Price | $46.37 | $22.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $75.58 | $30.55 |
| AVG Volume (30 Days) | 832.9K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $36.21 | $18.80 |
| Revenue Next Year | $20.80 | $11.70 |
| P/E Ratio | $425.29 | ★ $9.53 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $37.01 | $14.45 |
| 52 Week High | $112.54 | $28.35 |
| Indicator | LIF | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 50.23 |
| Support Level | $37.41 | $21.51 |
| Resistance Level | $47.43 | $22.91 |
| Average True Range (ATR) | 2.12 | 0.61 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 58.78 | 59.02 |
Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.